TNXP News and Press, Tonix Pharmaceuticals Holding Corp. From 03/03/26

BERKELEY HEIGHTS, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that it has received approval from Nasdaq to transfer the listing of its common stock fro...

2026-02-25 09:15:00 ET Tonix Pharmaceuticals (NASDAQ: TNXP) announced that its management team will participate in two upcoming investor conferences in March 2026. Seth Lederman, M.D., president and chief executive officer, will deliver a company presentation at the TD Cowen 46th Annual...

BERKELEY HEIGHTS, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that the management team will participate in two upcoming investor conferences in March 20...

2026-01-30 09:15:00 ET Tonix Pharmaceuticals (NASDAQ: TNXP) announced the presentation of clinical data for TONMYA(TM), previously investigated as TNX-102 SL, at the 2026 Non-Opioid Pain Therapeutics Summit held Jan. 29, 2026, in Boston. The data were drawn from RESILIENT, a 14-week Pha...

TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed for bedtime dosing bypasses first-pass metabolism, optimizing parent-drug exposure during sleep and decreasing levels of the persistent ac...

2026-01-20 08:42:52 ET Thesis: Tonix needs revenue growth What investors want to see is Tonix Pharmaceuticals ( TNXP ) move away from a cash-burning R&D company and into having more of a recurring revenue base from its current approved drugs. As of now, the current revenue b...

2026-01-06 09:25:00 ET Tonix Pharmaceuticals (NASDAQ: TNXP) announced that its management team will present and host investor meetings at multiple January investor conferences, including the Sachs Associates 9th Annual Neuroscience Innovation Forum and Biotech Showcase 2026, both held i...

2026-01-06 09:25:00 ET Tonix Pharmaceuticals (NASDAQ: TNXP) announced that its management team will present and host investor meetings at multiple January investor conferences, including the Sachs Associates 9th Annual Neuroscience Innovation Forum and Biotech Showcase 2026, both held i...

BERKELEY HEIGHTS, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully integrated, commercial biotechnology company, announced today that Tonix management will present and host investor meetings at the following January 2026 in...

2025-12-29 11:15:00 ET Tonix Pharmaceuticals (NASDAQ: TNXP) provided program updates on TNX-4800, a long-acting human monoclonal antibody designed for seasonal prophylaxis against Lyme disease, which targets the outer surface protein A of Borrelia burgdorferi , the bacterium that ca...